| Old Articles: <Older 54191-54200 Newer> |
|---|
 |
The Motley Fool
December 16, 2011
Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.   |
The Motley Fool
December 16, 2011
Matt Koppenheffer |
Regions Financial's Stock Was Clobbered by 2011 It was a tough year for Regions Financial shareholders. |
The Motley Fool
December 16, 2011
Chris Hill |
1 Thing Apple Shareholders Should Be Worried About Nell Minow discusses why shareholders should be concerned about Apple CEO Tim Cook's compensation package and other topics. |
The Motley Fool
December 16, 2011
Anand Chokkavelu |
Why the Dow Tanked This Week Breaking down the Dow. While only two stocks were up more than 2% (Pfizer up 2.3% and Travelers up 2.2%), five Dow stocks were down more than 7%. |
The Motley Fool
December 16, 2011
Evan Niu |
Why Does the Netbook Still Exist? Dell throws in the towel on consumer netbooks. |
The Motley Fool
December 16, 2011
Anders Bylund |
Adobe Ain't No Flash in the Pan Who needs proprietary technologies when you can milk industry standards instead? |
The Motley Fool
December 16, 2011
Christopher Barker |
You Are All Wrong About Commodity Demand Our analyst questions whether the exodus from commodities has created an opportunity. |
The Motley Fool
December 16, 2011
Evan Niu |
Did You Buy Zynga Today? Today was Zynga's first day trading in public. |
The Motley Fool
December 16, 2011
Seth Jayson |
Fool Cheat Sheet: Accenture Earnings Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Accenture is outperform, with an average price target of $62.79. |
The Motley Fool
December 16, 2011
Jim Royal |
Rising Star Buy: TripAdvisor This fast-growing company looks like a star. |
| <Older 54191-54200 Newer> Return to current articles. |
